-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Ginkgo Bioworks (NYSE:DNA) Trading 7.1% Higher
Ginkgo Bioworks (NYSE:DNA) Trading 7.1% Higher
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) traded up 7.1% during mid-day trading on Monday . The stock traded as high as $3.15 and last traded at $3.15. 827,671 shares traded hands during trading, a decline of 96% from the average session volume of 21,081,771 shares. The stock had previously closed at $2.94.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on the stock. Jefferies Financial Group cut their price objective on shares of Ginkgo Bioworks from $11.50 to $4.35 in a report on Thursday, June 16th. Raymond James increased their price target on shares of Ginkgo Bioworks from $11.50 to $14.50 and gave the company an "outperform" rating in a report on Tuesday, August 16th. Bank of America cut shares of Ginkgo Bioworks from a "neutral" rating to an "underperform" rating and set a $3.00 price target on the stock. in a report on Wednesday, May 18th. Finally, BTIG Research increased their price target on shares of Ginkgo Bioworks from $5.00 to $6.00 and gave the company a "buy" rating in a report on Tuesday, August 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $8.69.
Get Ginkgo Bioworks alerts:Ginkgo Bioworks Stock Up 7.8 %
The company has a market capitalization of $5.66 billion, a PE ratio of -1.62 and a beta of 1.84. The company's 50 day moving average is $2.96 and its two-hundred day moving average is $3.11. The company has a quick ratio of 11.78, a current ratio of 11.84 and a debt-to-equity ratio of 0.03.
Hedge Funds Weigh In On Ginkgo Bioworks
A number of institutional investors and hedge funds have recently made changes to their positions in DNA. B. Riley Wealth Management Inc. lifted its holdings in shares of Ginkgo Bioworks by 310.9% in the 2nd quarter. B. Riley Wealth Management Inc. now owns 48,900 shares of the company's stock worth $116,000 after acquiring an additional 37,000 shares during the last quarter. Amundi lifted its holdings in shares of Ginkgo Bioworks by 102.5% in the 2nd quarter. Amundi now owns 119,480 shares of the company's stock worth $369,000 after acquiring an additional 60,469 shares during the last quarter. Verition Fund Management LLC lifted its holdings in shares of Ginkgo Bioworks by 22.8% in the 2nd quarter. Verition Fund Management LLC now owns 47,361 shares of the company's stock worth $113,000 after acquiring an additional 8,780 shares during the last quarter. Legal & General Group Plc bought a new stake in shares of Ginkgo Bioworks in the 2nd quarter worth about $599,000. Finally, Centiva Capital LP bought a new stake in shares of Ginkgo Bioworks in the 2nd quarter worth about $99,000. 53.37% of the stock is owned by hedge funds and other institutional investors.About Ginkgo Bioworks
(Get Rating)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
See Also
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 3 Biotech Stocks Gaining Momentum
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) traded up 7.1% during mid-day trading on Monday . The stock traded as high as $3.15 and last traded at $3.15. 827,671 shares traded hands during trading, a decline of 96% from the average session volume of 21,081,771 shares. The stock had previously closed at $2.94.
銀杏生物工程控股公司(紐約證券交易所代碼：DNA-GET評級)週一午盤交易中上漲7.1%。該股一度漲至3.15美元，最後報3.15美元。827,671股股票在交易中成交，較21,081,771股的平均成交量下降96%。該股此前收盤價為2.94美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
A number of equities research analysts have weighed in on the stock. Jefferies Financial Group cut their price objective on shares of Ginkgo Bioworks from $11.50 to $4.35 in a report on Thursday, June 16th. Raymond James increased their price target on shares of Ginkgo Bioworks from $11.50 to $14.50 and gave the company an "outperform" rating in a report on Tuesday, August 16th. Bank of America cut shares of Ginkgo Bioworks from a "neutral" rating to an "underperform" rating and set a $3.00 price target on the stock. in a report on Wednesday, May 18th. Finally, BTIG Research increased their price target on shares of Ginkgo Bioworks from $5.00 to $6.00 and gave the company a "buy" rating in a report on Tuesday, August 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $8.69.
一些股票研究分析師對該股進行了加碼。在6月16日星期四的一份報告中，傑富瑞金融集團將銀杏生物的股票目標價從11.50美元下調至4.35美元。雷蒙德·詹姆斯在8月16日(星期二)的一份報告中將銀杏生物工場的股票目標價從11.50美元上調至14.50美元，並給予該公司“跑贏大盤”的評級。美國銀行將銀杏生物的股票評級從“中性”下調至“表現不佳”，併為該股設定了3美元的目標價。在5月18日星期三的一份報告中。最後，BTIG Research在8月16日(星期二)的一份報告中將銀杏生物工場的股票目標價從5.00美元上調至6.00美元，並給予該公司“買入”評級。一名投資分析師對該股的評級為賣出，一名分析師給出了持有評級，六名分析師給出了該公司股票的買入評級。根據MarketBeat.com的數據，該公司目前的平均評級為“中等買入”，平均目標價為8.69美元.
Ginkgo Bioworks Stock Up 7.8 %
銀杏生物股份上漲7.8%
The company has a market capitalization of $5.66 billion, a PE ratio of -1.62 and a beta of 1.84. The company's 50 day moving average is $2.96 and its two-hundred day moving average is $3.11. The company has a quick ratio of 11.78, a current ratio of 11.84 and a debt-to-equity ratio of 0.03.
該公司市值為56.6億美元，市盈率為-1.62，貝塔係數為1.84。該公司的50日移動均線切入位在2.96美元，200日移動均線切入位在3.11美元。該公司的速動比率為11.78，流動比率為11.84，債務權益比為0.03。
Hedge Funds Weigh In On Ginkgo Bioworks
對衝基金參與銀杏生物工程
About Ginkgo Bioworks
關於銀杏生物工場
(Get Rating)
(獲取評級)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
銀杏生物工程控股公司及其子公司開發細胞編程平臺。它的平臺用於對細胞進行編程，以實現產品的生物生產，如新型療法、食品配料和從石油中提取的化學品。該公司服務於各種終端市場，包括特種化學品、農業、食品、消費品和藥品。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 3 Biotech Stocks Gaining Momentum
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- 免費獲取StockNews.com關於銀杏生物工程(DNA)的研究報告
- 3只被降級的必備股票放在你的觀察名單上
- 這是對第三季度收益報告季節的預期
- 3只生物科技股勢頭強勁
- 電子藝界能扭轉電子遊戲市場的低迷嗎？
- 美元將軍是美國小池塘裏的大魚。
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
接受《銀杏生物工場日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對銀杏生物工程和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧